Gilde sells Viroclinics to Parcom Capital

The company is now fully owned by Parcom. Following the transaction, the GP aims to allow the company to expand its services portfolio across other areas of research, such as hepatitis, polio and RSV, and increase its international reach.

In 2016, Parcom's partners led the firm's MBO and span out the business from insurance group NN. Following a first close in December 2015, the fund manager recently hit the €550m hard-cap for Parcom Buy-Out Fund V in June 2016, after nine months on the road.

Previous funding
Gilde acquired a majority stake in Viroclinics in 2013 via its Gilde Healthcare Services fund, backing the company's spin-out from the Erasmus University Medical Centre. Launched in March 2009, the Utrecht-based Gilde Healthcare Services fund held a final close on €50m in October 2011.

According to a statement, Viroclinics expanded its facilities, doubled its headcount and tripled its revenues during Gilde's ownership period.

Company
Based in Rotterdam, Viroclinics span out from the Erasmus University Medical Centre in 2001. The company is a virology CRO, focusing on the development of antiviral drugs and vaccines for viral infectious diseases.

The business generated €13.3m in revenues in 2016 with €2.6m in net profit. It employs 100 people.

People
Parcom Capital Management – Piet-Hein de Jager (partner).
Gilde Healthcare – Jasper van Gorp (managing partner).
Viroclinics Biosciences – Bob van Gemen (CEO).

Advisers
Acquirer – PwC (financial due diligence).
Vendor – William Blair (corporate finance).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• Exits
• Healthcare
• Benelux
• Secondary buyout
• Netherlands
• Gilde Investment Management